Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Considerations for targeting malignant stem cells in leukemia.

Monica L Guzman1, Craig T Jordan

  • 1Blood and Marrow Transplant Program, Markey Cancer Center, Division of Hematology/Oncology, University of Kentucky Medical Center, Lexington, Kentucky, USA.

Cancer Control : Journal of the Moffitt Cancer Center
|March 17, 2004
PubMed
Summary

Targeting leukemic stem cells (LSCs) is crucial for leukemia treatment. Understanding LSC biology can lead to more effective therapies that prevent disease relapse.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

eIF4E and Ezrin cooperate in pseudopods to drive a localized migratory translation program in acute myeloid leukemia.

bioRxiv : the preprint server for biology·2026
Same author

Access to CAR-T therapy in Latin America: Barriers, gaps, and pathways forward.

Seminars in immunology·2026
Same author

Preclinical evidence of anti-CD19 CAR-T cell in vitro and in vivo efficacy against CD19-expressing acute myeloid leukemia.

Current research in translational medicine·2026
Same author

Dual targeting of SLC25A51 and succinate dehydrogenase selectively depletes mitochondrial NAD<sup>+</sup> to eradicate KRAS-driven AML.

Cell metabolism·2026
Same author

The Nicotinamide Salvage Pathway is a Metabolic Vulnerability of High-Risk MDS Stem Cells.

bioRxiv : the preprint server for biology·2026
Same author

Targeting IL-1/IRAK1/4 signaling in acute myeloid leukemia stem cells following treatment and relapse.

Leukemia·2025

Area of Science:

  • Hematology
  • Cancer Biology
  • Stem Cell Research

Background:

  • Leukemic stem cells (LSCs) are identified in various leukemia types, including AML, CML, and ALL.
  • LSCs possess self-renewal, differentiation, and proliferation capabilities, similar to normal stem cells.
  • Evidence indicates LSCs are pivotal in initiating and sustaining leukemic disease.

Purpose of the Study:

  • To review the characteristic features of LSCs across different leukemias.
  • To explore novel molecular strategies for LSC ablation.

Main Methods:

  • Literature review of LSC characteristics.
  • Analysis of molecular approaches targeting LSCs.

Main Results:

  • Ablating LSCs shows potential in leukemia treatment.

Related Experiment Videos

  • Unique LSC features can be exploited for targeted therapies.

    • Conclusions:

    • Current therapies may not fully eliminate LSCs, risking disease progression or relapse.
    • Enhanced understanding of LSC biology is essential for developing superior therapeutic strategies.